NCT02324426View on ClinicalTrials.gov

CNS Uptake of Intranasal Glutathione

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Parkinson's Disease
Interventions
DRUG

Reduced Glutathione

200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.

Trial Locations (1)

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

University of Washington

OTHER

NCT02324426 - CNS Uptake of Intranasal Glutathione | Biotech Hunter | Biotech Hunter